Deciphera Pharmaceuticals (DCPH) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results
May 5, 2020 4:01 PM EDT- NDA for Ripretinib for the Treatment of Advanced GIST Under Review by U.S. FDA with PDUFA Date of August 13, 2020; Commercial Preparations Underway to Support Potential Launch -
- COVID-19 Business Update Provided; Clinical and Commercial Milestone Timing Affirmed -
- First Quarter 2020 Ended with Cash, Cash Equivalents and Marketable Securities of $691.5 Million; Cash Runway Expected into the Second Half of 2022 -
- Company to Host Conference Call Today at 4:30 PM ET -
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera... More
